Description
Supplemental Table 1. A table showing all primer sequences, antibodies and conditions used throughout our studies. (.xlsx file)
The following supplemental figures have high resolution and large (_lrg) versions:
Supplemental Fig. 1. Full uncropped immunblots for the data shown in Fig. 3a.
Supplemental Fig. 2. Full uncropped immunblots for the data shown in Fig. 3b.
Supplemental Fig. 3. Full uncropped immunblots for the data shown in Fig. 3d.
Supplemental Fig. 4. Full uncropped immunblots for the SEBTA-003 data shown in Fig. 3g.
Supplemental Fig. 5. Full uncropped immunblots for the UP-029 data shown in Fig. 3g.
Supplemental Fig. 6. Full uncropped immunblots for the data shown in Fig. 5i.
This copy of the Supplementary Material is subject to the same licence (CC BY-NC-ND) and embargo as the post-print and will be available here from 23/05/20.
The following supplemental figures have high resolution and large (_lrg) versions:
Supplemental Fig. 1. Full uncropped immunblots for the data shown in Fig. 3a.
Supplemental Fig. 2. Full uncropped immunblots for the data shown in Fig. 3b.
Supplemental Fig. 3. Full uncropped immunblots for the data shown in Fig. 3d.
Supplemental Fig. 4. Full uncropped immunblots for the SEBTA-003 data shown in Fig. 3g.
Supplemental Fig. 5. Full uncropped immunblots for the UP-029 data shown in Fig. 3g.
Supplemental Fig. 6. Full uncropped immunblots for the data shown in Fig. 5i.
This copy of the Supplementary Material is subject to the same licence (CC BY-NC-ND) and embargo as the post-print and will be available here from 23/05/20.
Date made available | 23 May 2019 |
---|---|
Publisher | Elsevier BV |